subject: quot;The new medicine on" commitments over 1 billion profit this year - on drugs - the pharmaceutical industries [print this page] quot;The new medicine on" commitments over 1 billion profit this year - on drugs - the pharmaceutical industries
March 9, after eight months before and after the final completion of the restructuring of Shanghai Medicine Formal resumption of trading, securities code starting from March 5, from "600 849" officially changed to "601,607." Ruling by the Pharmaceutical Group Chairman, said, the next biggest challenge is how to complete the internal market mechanism according to interoperability problems. It is learned that the end to the middle of next month, president of Shanghai Traditional Chinese Medicine will recruit, foreign acquisitions, the list of matters such as directors and board of supervisors issued a public notice in succession.
This is my first column pharmaceutical trading price of more than 16 billion yuan on the merger and reorganization items, the original Shanghai Traditional Chinese Medicine, Chinese medicine and Western medicine on the actual implementation of "Triple Play." After the reorganization of the "new medicine on the" market is expected to more than 30 billion yuan, becoming the largest value of A stock, covering the whole industrial chain of the pharmaceutical industry a comprehensive medical lead, the second largest in the country, second only to Sinopharm.
Committed over 1 billion yuan profit this year
Lui Ming Fang said the company's commitment to a profit of 1.03 billion yuan in 2010, exceeded the plan this year. 1,2 months of this year has reached performance goals, in January up 20% year on year performance.
It is understood, Shanghai state-owned assets will be launched this year, equity incentive pilot listed companies, the new incentive system on the drug and bring opportunities, the company also brewing in the affiliated business units to encourage competitive enterprises to realize the way over into incentive .
Through to the new Shanghai Traditional Chinese Medicine, shareholder structure has undergone significant changes, including a public offering, private equity, insurance and other institutions, including the proportion of outstanding shares may have been from less than 10% to 25%.
Ruling by reporters on the China Securities Journal said the next focus is on internal integration and external M & A synergies, which will change the internal operation mode, adjust the assessment mechanism; outside the company will increase the competitive advantage associated with the merger, such as a several months the project will be signed shortly.
The market next question whether the company was renamed the possible, said Lu Ming Fang, Shanghai Medical will not be renamed, will also follow the "Shanghai" piece of flagship business.
New president in place by the end of March
According to previous announcement of Shanghai Pharmaceutical, has started operation of new mechanism drugs comprehensive market reform, will create an open competitive selection president. Lui Ming Fang said the company's new president will be finalized at the end of this month, does not rule out the possibility to select from within the enterprise is still in progress.
"To candidates who exceeded our expectations," said Lu Ming Fang, the new Shanghai the first Chinese to do is to implement market-oriented mechanism. When the company reorganized last year developed a three-year action plan, the new president must be recognized that strategic planning.
New Shanghai Traditional Chinese Medicine will be held at the end of March the first general meeting of shareholders to elect a new board of directors, will develop the company targets high-level assessment. Lui Ming Fang said that the new governance structure, independent directors will be greater than non-independent directors, the company will recommend shareholders industry experts, academic medical experts to help business decisions.
